What is the legal and regulatory status of CJC-1295?

The honest bottom line first: CJC-1295 is a synthetic GHRH analog with no FDA marketing approval for any indication and no equivalent authorization from any comparable national regulator. It sits in a regulatory gap, lawful to study under research conditions but broadly unlawful to sell or use as a human therapeutic, banned at all times in sanctioned sport, and treated as an unauthorized medicine across other developed jurisdictions. The status is also live rather than settled: the molecule was removed from the FDA's Category 2 bulk-substances bucket in April 2026 and now awaits a Pharmacy Compounding Advisory Committee review.

Has CJC-1295 ever been approved by the FDA for any human therapeutic use?

No agency record shows CJC-1295 ever receiving FDA approval for any human therapeutic indication, and there is no approved New Drug Application or Biologics License Application on file for it. The published record describes only early-phase clinical investigation in the mid-2000s examining its pharmacokinetics and its ability to raise growth hormone and IGF-1, after which development as a finished product was discontinued. The absence of approval does not make the molecule contraband, since it is not a scheduled controlled drug, but it does close the door to lawful marketing, sale, or labeling for human use as a medicine.

• Approval applications: No approved NDA or BLA exists; no orphan-drug designation, investigational marketing authorization, or emergency-use status.
• Approval pathway not completed: FDA approval requires preclinical work, an Investigational New Drug application, sequential efficacy and safety trials, then formal marketing authorization; CJC-1295 reached only early-phase study.
• Facility-registration confusion: A supplier's FDA facility registration or claimed inspection speaks only to listing obligations and never constitutes approval of the product itself.

How does the FDA classify CJC-1295, and why does it fall outside approved-drug pathways?

Functionally the agency treats CJC-1295 as an unapproved new drug. Because the molecule is intended to affect the structure or function of the body by stimulating endogenous growth hormone release, it meets the statutory definition of a drug under the Federal Food, Drug, and Cosmetic Act and cannot escape that regulation by relabeling. The supplement pathway is also closed: a synthetic peptide first investigated as a drug, and the subject of an investigational application, is excluded from the dietary-supplement definition under the Act.

1. Statutory drug classification: The intended effect on body structure or function places CJC-1295 within the FFDCA drug definition, removing any "not a drug" relabeling option.
2. Dietary-supplement exclusion: Prior investigation as a drug under an investigational application excludes the peptide from the supplement definition, closing that route.
3. Misbranding hook: Adequate directions for safe use cannot be written for an unapproved indication, rendering any human-use version misbranded.
4. Adulteration hook: Production outside recognized current good manufacturing practice for a finished drug renders the product adulterated.

What is the status of CJC-1295 under the federal compounding framework and the FDA bulk substances lists?

Compounding is the one channel through which an unapproved substance can sometimes reach patients lawfully, and as of mid-2026 CJC-1295 has no lawful path through it. Section 503A permits a traditional pharmacy to compound from a bulk substance only when that substance is a component of an approved drug, carries a USP monograph, or appears on the FDA's Category 1 list; Section 503B sets a parallel framework for registered outsourcing facilities. CJC-1295 satisfies none of the first two routes, and its bulk-list placement is a live determination rather than a settled exclusion.

Is CJC-1295 prohibited in competitive sport under the WADA Prohibited List?

Within sport the answer is unambiguous: CJC-1295 is squarely prohibited. It is captured under the peptide hormones, growth factors, related substances, and mimetics category of the WADA Prohibited List, specifically as a growth-hormone-releasing hormone analog and growth-hormone secretagogue, the same family that includes other GHRH and GHRP compounds. The prohibition is total in time, which removes any off-season-then-discontinue compliance strategy.

• Prohibited at all times: The ban covers both in-competition and out-of-competition use, so off-season use followed by discontinuation does not restore compliance.
• Detection has improved: Anti-doping laboratories have refined methods targeting these short-acting secretagogues directly and through downstream biological markers, raising the practical risk of an adverse analytical finding.
• Sanction length: A finding for a non-specified substance of this type typically carries a multi-year period of ineligibility, varying with intent, cooperation, and prior violations.
• Separate from criminal law: The WADA prohibition governs sporting eligibility and sanctions, distinct from national drug scheduling, which does not list the peptide.

How is CJC-1295 commonly sold and labeled, and what legal significance does research-use-only labeling carry?

Almost all CJC-1295 in circulation is sold by chemical and peptide suppliers under labeling stating it is for research or laboratory use only and not for human consumption. That labeling is best understood as a commercial disclaimer rather than a regulatory authorization. It signals that the seller is not making therapeutic claims and is attempting to position the sale outside drug regulation, but it does not transform an unapproved drug into a lawful product. Regulators have repeatedly held that intent and foreseeable use control, so surrounding marketing or dosing guidance that points to human injection will not insulate a seller from misbranding exposure.

What legal risks do individuals and sellers face when importing, distributing, or possessing CJC-1295?

The legal exposure around CJC-1295 scales sharply with the role a person plays. Because the peptide is not a scheduled controlled substance, simple personal possession is generally not a federal drug-scheduling crime, a meaningful distinction from substances such as anabolic steroids. The exposure begins at the border and grows steeply with commercial involvement, reaching its heaviest weight on distributors, marketers, and prescribing clinicians.

How does the regulatory treatment of CJC-1295 differ across major jurisdictions outside the United States?

Outside the United States the outcome is broadly similar but reached through different regulatory machinery, and a few jurisdictions are notably stricter. The common thread is consistent: because CJC-1295 has never completed an approval pathway anywhere, every developed regulator handles it as an unauthorized or unapproved medicine rather than a legitimate therapeutic. What differs is the specific legal label, the severity of penalties, and the willingness to pursue criminal rather than administrative consequences.